BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23529250)

  • 1. [Clinical characteristics and outcomes of 31 patients with primary bone lymphoma].
    Zhu Y; Yue C; Wu B; Ping B
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Mar; 33(3):444-7. PubMed ID: 23529250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
    Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
    Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
    J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
    Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
    Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience.
    Wu H; Zhang L; Shao H; Sokol L; Sotomayor E; Letson D; Bui MM
    Br J Haematol; 2014 Jul; 166(1):60-8. PubMed ID: 24673481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study.
    Cai L; Stauder MC; Zhang YJ; Poortmans P; Li YX; Constantinou N; Thariat J; Kadish SP; Nguyen TD; Kirova YM; Ghadjar P; Weber DC; Bertran VT; Ozsahin M; Mirimanoff RO
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):284-91. PubMed ID: 22079728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
    Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
    Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.
    Beal K; Allen L; Yahalom J
    Cancer; 2006 Jun; 106(12):2652-6. PubMed ID: 16700039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of 82 cases of primary mediastinal large B cell lymphoma].
    Wang J; Hu C; Zhao Y; Yi P; Huang M; Zhang G
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):491-4. PubMed ID: 24985169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.
    Shimada K; Matsue K; Yamamoto K; Murase T; Ichikawa N; Okamoto M; Niitsu N; Kosugi H; Tsukamoto N; Miwa H; Asaoku H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T
    J Clin Oncol; 2008 Jul; 26(19):3189-95. PubMed ID: 18506023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era.
    Takahashi H; Tomita N; Yokoyama M; Tsunoda S; Yano T; Murayama K; Hashimoto C; Tamura K; Sato K; Ishigatsubo Y
    Cancer; 2012 Sep; 118(17):4166-72. PubMed ID: 22213346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
    Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.